Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer
This Review Article provides a multi-stakeholder view on the current status of neoadjuvant therapy in lung cancer. Given the success of oncogene-targeted therapy and immunotherapy for patients with advanced lung cancer, there is a renewed interest in studying these agents in earlier disease settings...
Saved in:
| Published in | Journal of thoracic oncology Vol. 13; no. 12; pp. 1818 - 1831 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
Elsevier Inc
01.12.2018
Copyright by the International Association for the Study of Lung Cancer |
| Subjects | |
| Online Access | Get full text |
| ISSN | 1556-0864 1556-1380 1556-1380 |
| DOI | 10.1016/j.jtho.2018.09.017 |
Cover
Loading…
| Abstract | This Review Article provides a multi-stakeholder view on the current status of neoadjuvant therapy in lung cancer. Given the success of oncogene-targeted therapy and immunotherapy for patients with advanced lung cancer, there is a renewed interest in studying these agents in earlier disease settings with the opportunity to have an even greater impact on patient outcomes. There are unique opportunities and challenges with the neoadjuvant approach to drug development. To achieve more rapid knowledge turns, study designs, endpoints, and definitions of pathologic response should be standardized and harmonized. Continued dialogue with all stakeholders will be critical to design and test novel induction strategies, which could expedite drug development for patients with early lung cancer who are at high risk for metastatic recurrence. |
|---|---|
| AbstractList | ABSTRACTThis Review Article provides a multi-stakeholder view on the current status of neoadjuvant therapy in lung cancer. Given the success of oncogene-targeted therapy and immunotherapy for patients with advanced lung cancer, there is a renewed interest in studying these agents in earlier disease settings with the opportunity to have an even greater impact on patient outcomes. There are unique opportunities and challenges with the neoadjuvant approach to drug development. To achieve more rapid knowledge turns, study designs, endpoints, and definitions of pathologic response should be standardized and harmonized. Continued dialogue with all stakeholders will be critical to design and test novel induction strategies, which could expedite drug development for patients with early lung cancer who are at high risk for metastatic recurrence. This Review Article provides a multi-stakeholder view on the current status of neoadjuvant therapy in lung cancer. Given the success of oncogene-targeted therapy and immunotherapy for patients with advanced lung cancer, there is a renewed interest in studying these agents in earlier disease settings with the opportunity to have an even greater impact on patient outcomes. There are unique opportunities and challenges with the neoadjuvant approach to drug development. To achieve more rapid knowledge turns, study designs, endpoints, and definitions of pathologic response should be standardized and harmonized. Continued dialogue with all stakeholders will be critical to design and test novel induction strategies, which could expedite drug development for patients with early lung cancer who are at high risk for metastatic recurrence. This Review Article provides a multi-stakeholder view on the current status of neoadjuvant therapy in lung cancer. Given the success of oncogene-targeted therapy and immunotherapy for patients with advanced lung cancer, there is a renewed interest in studying these agents in earlier disease settings with the opportunity to have an even greater impact on patient outcomes. There are unique opportunities and challenges with the neoadjuvant approach to drug development. To achieve more rapid knowledge turns, study designs, endpoints, and definitions of pathologic response should be standardized and harmonized. Continued dialogue with all stakeholders will be critical to design and test novel induction strategies, which could expedite drug development for patients with early lung cancer who are at high risk for metastatic recurrence.This Review Article provides a multi-stakeholder view on the current status of neoadjuvant therapy in lung cancer. Given the success of oncogene-targeted therapy and immunotherapy for patients with advanced lung cancer, there is a renewed interest in studying these agents in earlier disease settings with the opportunity to have an even greater impact on patient outcomes. There are unique opportunities and challenges with the neoadjuvant approach to drug development. To achieve more rapid knowledge turns, study designs, endpoints, and definitions of pathologic response should be standardized and harmonized. Continued dialogue with all stakeholders will be critical to design and test novel induction strategies, which could expedite drug development for patients with early lung cancer who are at high risk for metastatic recurrence. |
| Author | Jarkowski, Anthony Travis, William D. Botwood, Nicholas Taube, Janis M. Rusch, Valerie Diehn, Max Hirsch, Fred R. McCoach, Caroline E. Berry, Donald A. Stahel, Rolf A. Swisher, Stephen Leavey, Patrick J. Blakely, Collin M. Rizvi, Naiyer A. Carbone, David P. Drezner, Nicole L. Schwartz, Lawrence H. Chaft, Jamie E. Eberhardt, Wilfried E.E. Wistuba, Ignacio I. Gianni, Luca Perez, Edith A. Cross, Darren A.E. Redman, Mary W. Aisner, Dara L. Bergh, Jonas Scagliotti, Giorgio V. Blumenthal, Gideon M. Felip, Enriqueta Doebele, Robert C. Pignatti, Francesco Prowell, Tatiana M. Keller, Steven P. Aerts, Hugo J.W.L. Bunn, Paul A. Malik, Shakun Keegan, Patricia Rosell, Rafael de Ruysscher, Dirk Wynes, Murry W. Kris, Mark G. Sridhara, Rajeshwari Wiens, Jacinta R. |
| AuthorAffiliation | Department of Internal Medicine, Division of Medical Oncology, The Ohio State University, Columbus, Ohio Division of Hematology and Oncology, Columbia University Medical Center, New York, New York Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas Southwest Oncology Group Statistical Center/Fred Hutchinson Cancer Research Center, Seattle, Washington Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York Comprehensive Cancer Center, Zürich, Switzerland Thoracic Cancers, Bristol-Myers Squibb, Lawrenceville, New Jersey Center for Drug Evaluation and Research, United States Food and Drug Administration, Silver Spring, Maryland Johns Hopkins School of Medicine, Department of Dermatology, Division of Dermatopathology, Baltimore, Maryland Catalan Institute of Oncology, Germans Trias i Pujol Health Sciences Institute and Hospital, Badalona, Barcelona, Spain European Medicines Agency, London, Unit |
| AuthorAffiliation_xml | – name: Hematology and Oncology, Mayo Clinic, Rochester, Minnesota – name: Center for Drug Evaluation and Research, United States Food and Drug Administration, Silver Spring, Maryland – name: Southwest Oncology Group Statistical Center/Fred Hutchinson Cancer Research Center, Seattle, Washington – name: Oncology Clinical Development, Bristol-Myers Squibb, Lawrenceville, New Jersey – name: Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas – name: Department of Radiology, New York Presbyterian Hospital, Columbia University College of Physicians and Surgeons, New York, New York – name: Medical Oncology Department, Vall d' Hebron University Hospital, Vall d' Hebron Institute of Oncology, Barcelona, Spain – name: AstraZeneca Oncology Innovative Medicines, Alderley Park, Macclesfield, Cheshire, United Kingdom – name: Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York – name: Division of Hematology and Oncology, Columbia University Medical Center, New York, New York – name: Thoracic Cancers, Bristol-Myers Squibb, Lawrenceville, New Jersey – name: Department of Pathology, University of Colorado, Aurora, Colorado – name: Cancer Therapeutics Evaluation Program, Rockville, Maryland – name: Johns Hopkins School of Medicine, Department of Dermatology, Division of Dermatopathology, Baltimore, Maryland – name: Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas – name: European Medicines Agency, London, United Kingdom – name: Department of Radiation Oncology, Stanford Cancer Institute, and Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, California – name: Department of Medical Oncology, Ospedale San Raffaele, Milan, Italy – name: Department of Medical Oncology, West German Cancer Centre, University Hospital, University Duisburg-Essen, Ruhrlandklinik, Essen, Germany – name: Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York – name: Division of Medical Oncology, University of Colorado Cancer Center, Aurora, Colorado – name: Catalan Institute of Oncology, Germans Trias i Pujol Health Sciences Institute and Hospital, Badalona, Barcelona, Spain – name: Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York – name: Merck, Rahway, New Jersey – name: Department of Internal Medicine, Division of Medical Oncology, The Ohio State University, Columbus, Ohio – name: Comprehensive Cancer Center, Zürich, Switzerland – name: International Association for the Study of Lung Cancer, Aurora, Colorado – name: Medical Oncology Division, Department of Oncology at San Luigi Hospital, University of Torino, Orbassano, Italy |
| Author_xml | – sequence: 1 givenname: Gideon M. surname: Blumenthal fullname: Blumenthal, Gideon M. email: gideon.blumenthal@fda.hhs.gov organization: Center for Drug Evaluation and Research, United States Food and Drug Administration, Silver Spring, Maryland – sequence: 2 givenname: Paul A. surname: Bunn fullname: Bunn, Paul A. organization: Division of Medical Oncology, University of Colorado Cancer Center, Aurora, Colorado – sequence: 3 givenname: Jamie E. surname: Chaft fullname: Chaft, Jamie E. organization: Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York – sequence: 4 givenname: Caroline E. surname: McCoach fullname: McCoach, Caroline E. organization: Department of Medicine, University of California, San Francisco, California; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, California – sequence: 5 givenname: Edith A. surname: Perez fullname: Perez, Edith A. organization: Hematology and Oncology, Mayo Clinic, Rochester, Minnesota – sequence: 6 givenname: Giorgio V. surname: Scagliotti fullname: Scagliotti, Giorgio V. organization: Medical Oncology Division, Department of Oncology at San Luigi Hospital, University of Torino, Orbassano, Italy – sequence: 7 givenname: David P. surname: Carbone fullname: Carbone, David P. organization: Department of Internal Medicine, Division of Medical Oncology, The Ohio State University, Columbus, Ohio – sequence: 8 givenname: Hugo J.W.L. surname: Aerts fullname: Aerts, Hugo J.W.L. organization: Department of Radiation Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts; Department of Radiology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts – sequence: 9 givenname: Dara L. surname: Aisner fullname: Aisner, Dara L. organization: Department of Pathology, University of Colorado, Aurora, Colorado – sequence: 10 givenname: Jonas surname: Bergh fullname: Bergh, Jonas organization: Department of Oncology-Pathology, Cancer Centrum Karolinska, Karolinska Institutet, Stockholm, Sweden; Department of Oncology, Radiumhemmet, Karolinska University Hospital, Stockholm, Sweden – sequence: 11 givenname: Donald A. surname: Berry fullname: Berry, Donald A. organization: Berry Consultants, LLC, Austin, Texas; University of Texas MD Anderson Cancer Center, Houston, Texas – sequence: 12 givenname: Anthony surname: Jarkowski fullname: Jarkowski, Anthony organization: Oncology Clinical Development, Bristol-Myers Squibb, Lawrenceville, New Jersey – sequence: 13 givenname: Nicholas surname: Botwood fullname: Botwood, Nicholas organization: Thoracic Cancers, Bristol-Myers Squibb, Lawrenceville, New Jersey – sequence: 14 givenname: Darren A.E. surname: Cross fullname: Cross, Darren A.E. organization: AstraZeneca Oncology Innovative Medicines, Alderley Park, Macclesfield, Cheshire, United Kingdom – sequence: 15 givenname: Max surname: Diehn fullname: Diehn, Max organization: Department of Radiation Oncology, Stanford Cancer Institute, and Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, California – sequence: 16 givenname: Nicole L. surname: Drezner fullname: Drezner, Nicole L. organization: Brain Tumor Institute, Children's National Health System, Children's National Medical Center, Washington, DC; Office of Hematology Oncology Products, Food and Drug Administration, Silver Spring, Maryland – sequence: 17 givenname: Robert C. surname: Doebele fullname: Doebele, Robert C. organization: Division of Medical Oncology, University of Colorado Cancer Center, Aurora, Colorado – sequence: 18 givenname: Collin M. surname: Blakely fullname: Blakely, Collin M. organization: Department of Medicine, University of California, San Francisco, California; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, California – sequence: 19 givenname: Wilfried E.E. surname: Eberhardt fullname: Eberhardt, Wilfried E.E. organization: Department of Medical Oncology, West German Cancer Centre, University Hospital, University Duisburg-Essen, Ruhrlandklinik, Essen, Germany – sequence: 20 givenname: Enriqueta surname: Felip fullname: Felip, Enriqueta organization: Medical Oncology Department, Vall d' Hebron University Hospital, Vall d' Hebron Institute of Oncology, Barcelona, Spain – sequence: 21 givenname: Luca surname: Gianni fullname: Gianni, Luca organization: Department of Medical Oncology, Ospedale San Raffaele, Milan, Italy – sequence: 22 givenname: Steven P. surname: Keller fullname: Keller, Steven P. organization: Merck, Rahway, New Jersey – sequence: 23 givenname: Patrick J. surname: Leavey fullname: Leavey, Patrick J. organization: Children's Health Children's Medical Center Dallas, Texas; University of Texas Southwestern Medical Center, Dallas, Texas – sequence: 24 givenname: Shakun surname: Malik fullname: Malik, Shakun organization: Cancer Therapeutics Evaluation Program, Rockville, Maryland – sequence: 25 givenname: Francesco surname: Pignatti fullname: Pignatti, Francesco organization: European Medicines Agency, London, United Kingdom – sequence: 26 givenname: Tatiana M. surname: Prowell fullname: Prowell, Tatiana M. organization: Center for Drug Evaluation and Research, United States Food and Drug Administration, Silver Spring, Maryland – sequence: 27 givenname: Mary W. surname: Redman fullname: Redman, Mary W. organization: Southwest Oncology Group Statistical Center/Fred Hutchinson Cancer Research Center, Seattle, Washington – sequence: 28 givenname: Naiyer A. surname: Rizvi fullname: Rizvi, Naiyer A. organization: Division of Hematology and Oncology, Columbia University Medical Center, New York, New York – sequence: 29 givenname: Rafael surname: Rosell fullname: Rosell, Rafael organization: Catalan Institute of Oncology, Germans Trias i Pujol Health Sciences Institute and Hospital, Badalona, Barcelona, Spain – sequence: 30 givenname: Valerie surname: Rusch fullname: Rusch, Valerie organization: Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York – sequence: 31 givenname: Dirk surname: de Ruysscher fullname: de Ruysscher, Dirk organization: KU Leuven-University of Leuven, Department of Radiation Oncology, Leuven, Belgium; Department of Radiation Oncology (MAASTRO), Maastricht University Medical Centre, GROW, Maastricht, The Netherlands – sequence: 32 givenname: Lawrence H. surname: Schwartz fullname: Schwartz, Lawrence H. organization: Department of Radiology, New York Presbyterian Hospital, Columbia University College of Physicians and Surgeons, New York, New York – sequence: 33 givenname: Rajeshwari surname: Sridhara fullname: Sridhara, Rajeshwari organization: Center for Drug Evaluation and Research, United States Food and Drug Administration, Silver Spring, Maryland – sequence: 34 givenname: Rolf A. surname: Stahel fullname: Stahel, Rolf A. organization: Comprehensive Cancer Center, Zürich, Switzerland – sequence: 35 givenname: Stephen surname: Swisher fullname: Swisher, Stephen organization: Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas – sequence: 36 givenname: Janis M. surname: Taube fullname: Taube, Janis M. organization: Johns Hopkins School of Medicine, Department of Dermatology, Division of Dermatopathology, Baltimore, Maryland – sequence: 37 givenname: William D. surname: Travis fullname: Travis, William D. organization: Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York – sequence: 38 givenname: Patricia surname: Keegan fullname: Keegan, Patricia organization: Center for Drug Evaluation and Research, United States Food and Drug Administration, Silver Spring, Maryland – sequence: 39 givenname: Jacinta R. surname: Wiens fullname: Wiens, Jacinta R. organization: International Association for the Study of Lung Cancer, Aurora, Colorado – sequence: 40 givenname: Ignacio I. surname: Wistuba fullname: Wistuba, Ignacio I. organization: Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas – sequence: 41 givenname: Murry W. surname: Wynes fullname: Wynes, Murry W. organization: International Association for the Study of Lung Cancer, Aurora, Colorado – sequence: 42 givenname: Fred R. surname: Hirsch fullname: Hirsch, Fred R. organization: Division of Medical Oncology, University of Colorado Cancer Center, Aurora, Colorado – sequence: 43 givenname: Mark G. surname: Kris fullname: Kris, Mark G. organization: Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/30268698$$D View this record in MEDLINE/PubMed http://kipublications.ki.se/Default.aspx?queryparsed=id:139661769$$DView record from Swedish Publication Index |
| BookMark | eNp9kcuO0zAUQC00iHnAD7BAWbJJuHbsxJHYoGoGkCpAYlhbTnxL3Unj4Eer-XtcpcOCxSwsW9E5N9I91-RichMS8pZCRYE2H3bVLm5dxYDKCroKaPuCXFEhmpLWEi7Ob5ANvyTXIewAuAAuX5HLGlgjm05ekfUqeY9TLH5GHVMo9GSKuxSTx-IH-jDjEO0BQ-Gm4hs6bXbpoDN9v0Wv58fCTsU6Tb-LlZ4G9K_Jy40eA7453zfk193t_epLuf7--evq07ocBO9EiWboad81mjPKQfYMwBhT864VtG-pRGO0QT3QtuObDeuxrhsONeOsFQyErm9IucwNR5xTr2Zv99o_KqetOn96yC9UXArGZebfL_zs3Z-EIaq9DQOOo57QpaAYpYK1nDU0o-_OaOr3aP6NftpYBuQCDN6F4HGjBptXZ90UvbajoqBOcdROneKoUxwFncpxssr-U5-mPyvxRTq6MeYiD2M6oldb1GPcZoLxWna8PCk0LxLKfEBk7eOiYe5wsNkIg8UcyVifmyrj7HN__QuGAre3 |
| CitedBy_id | crossref_primary_10_1016_j_lungcan_2023_01_002 crossref_primary_10_3389_fgene_2021_642981 crossref_primary_10_56050_01205498_2316 crossref_primary_10_35366_103454 crossref_primary_10_1016_j_trecan_2023_07_011 crossref_primary_10_1016_j_jtho_2023_08_011 crossref_primary_10_1186_s13643_025_02767_6 crossref_primary_10_1016_j_lungcan_2020_03_012 crossref_primary_10_1016_j_jtho_2018_11_017 crossref_primary_10_3390_cancers14184363 crossref_primary_10_1093_jncics_pkae021 crossref_primary_10_1016_j_jtocrr_2021_100221 crossref_primary_10_1097_JS9_0000000000001580 crossref_primary_10_3390_toxins13020149 crossref_primary_10_1016_j_jtho_2021_03_029 crossref_primary_10_1016_j_wnsx_2024_100391 crossref_primary_10_3389_fimmu_2024_1412693 crossref_primary_10_1093_icvts_ivae213 crossref_primary_10_1111_ajco_13665 crossref_primary_10_1186_s12951_021_01163_1 crossref_primary_10_1002_adtp_202400163 crossref_primary_10_1200_EDBK_280807 crossref_primary_10_1134_S107036322407017X crossref_primary_10_1007_s00432_023_05073_7 crossref_primary_10_1158_1078_0432_CCR_19_2379 crossref_primary_10_1177_10781552241260864 crossref_primary_10_1007_s13402_023_00914_6 crossref_primary_10_1016_j_jtcvs_2022_10_056 crossref_primary_10_1186_s12885_024_13142_4 crossref_primary_10_3390_jcm11092629 crossref_primary_10_5858_arpa_2021_0313_OA crossref_primary_10_6004_jnccn_2022_7021 crossref_primary_10_3390_diagnostics12051086 crossref_primary_10_1186_s12957_020_01933_5 crossref_primary_10_1002_onco_13590 crossref_primary_10_1007_s11864_022_00994_w crossref_primary_10_1093_ejcts_ezz287 crossref_primary_10_2217_imt_2022_0302 crossref_primary_10_2147_OTT_S266155 crossref_primary_10_1002_mco2_213 crossref_primary_10_1016_j_athoracsur_2021_06_069 crossref_primary_10_3390_cancers16162885 crossref_primary_10_1186_s12889_022_13281_y crossref_primary_10_1038_s41416_020_01069_z crossref_primary_10_1097_COC_0000000000001046 crossref_primary_10_1038_s41571_021_00501_4 crossref_primary_10_1007_s11748_020_01384_5 crossref_primary_10_1136_jitc_2022_005036 crossref_primary_10_1186_s12957_023_03194_4 crossref_primary_10_1007_s40265_022_01721_3 crossref_primary_10_1007_s00761_018_0488_7 crossref_primary_10_1007_s00330_023_09922_4 crossref_primary_10_1002_mco2_722 crossref_primary_10_1093_dote_doac031 crossref_primary_10_1111_1759_7714_14209 crossref_primary_10_1158_1078_0432_CCR_20_3285 crossref_primary_10_2217_fon_2021_0549 crossref_primary_10_1007_s43441_024_00706_6 crossref_primary_10_1021_acsanm_4c00580 crossref_primary_10_1111_crj_13761 crossref_primary_10_3389_fonc_2023_1286104 crossref_primary_10_1093_jnci_djaa217 crossref_primary_10_3390_cancers13164035 crossref_primary_10_1016_j_jtho_2024_06_010 crossref_primary_10_1111_his_14855 crossref_primary_10_1200_JCO_21_02660 crossref_primary_10_2217_fon_2023_0170 crossref_primary_10_1186_s12885_022_09908_3 crossref_primary_10_1016_j_critrevonc_2023_104243 crossref_primary_10_1097_PAP_0000000000000441 crossref_primary_10_1200_JCO_21_01446 crossref_primary_10_1186_s12967_022_03857_y crossref_primary_10_2217_fon_2020_1098 crossref_primary_10_3389_fpubh_2023_1054200 crossref_primary_10_1016_j_jtho_2020_01_005 crossref_primary_10_1016_j_modpat_2023_100302 crossref_primary_10_1016_j_jtcvs_2020_04_033 crossref_primary_10_1111_resp_14613 crossref_primary_10_1002_cam4_4889 crossref_primary_10_1016_j_jtcvs_2020_05_119 crossref_primary_10_1002_path_5528 crossref_primary_10_1016_j_cllc_2020_03_003 crossref_primary_10_1158_1078_0432_CCR_20_1129 crossref_primary_10_1016_j_jtocrr_2022_100420 crossref_primary_10_1111_jcmm_15274 crossref_primary_10_1016_j_lungcan_2021_02_004 crossref_primary_10_1038_s41698_022_00301_8 crossref_primary_10_1038_s41430_022_01191_6 crossref_primary_10_2482_haigan_64_263 crossref_primary_10_1200_JCO_24_00071 crossref_primary_10_3390_cancers12113459 crossref_primary_10_1016_j_ijsu_2022_106680 crossref_primary_10_1016_j_jtho_2023_07_006 crossref_primary_10_36516_jocass_1427896 crossref_primary_10_1007_s00262_023_03560_x crossref_primary_10_1016_j_gore_2021_100887 crossref_primary_10_1093_oncolo_oyad125 crossref_primary_10_1016_j_ejca_2021_01_006 crossref_primary_10_1007_s40265_024_02111_7 crossref_primary_10_3892_ol_2023_14156 crossref_primary_10_3389_fgene_2020_00768 crossref_primary_10_1016_j_jtho_2019_02_029 crossref_primary_10_3389_fonc_2022_969545 crossref_primary_10_1200_JCO_22_02509 crossref_primary_10_3389_fimmu_2024_1432813 crossref_primary_10_1093_icvts_ivac103 crossref_primary_10_3390_cancers16010156 crossref_primary_10_1016_j_modpat_2023_100209 crossref_primary_10_3389_fonc_2022_848779 crossref_primary_10_3389_fonc_2022_959637 crossref_primary_10_4236_ijcm_2024_1512036 crossref_primary_10_1016_j_jtho_2022_04_012 crossref_primary_10_2217_fon_2019_0025 crossref_primary_10_1016_j_jtcvs_2021_04_056 crossref_primary_10_1177_1758835920973567 crossref_primary_10_3389_fonc_2023_1164543 crossref_primary_10_1038_s41379_021_00871_1 crossref_primary_10_1055_s_0039_1679884 crossref_primary_10_1038_s41379_021_00777_y crossref_primary_10_1111_1759_7714_14127 crossref_primary_10_3390_cancers13205048 crossref_primary_10_1186_s40644_025_00856_2 crossref_primary_10_1200_JCO_19_00075 crossref_primary_10_1136_jitc_2022_005344 crossref_primary_10_1016_S1470_2045_20_30146_7 crossref_primary_10_1016_j_jtocrr_2024_100776 crossref_primary_10_1016_j_biopha_2020_111213 crossref_primary_10_1200_EDBK_237839 crossref_primary_10_1111_1759_7714_13728 crossref_primary_10_1186_s12885_021_08983_2 crossref_primary_10_1007_s00432_020_03188_9 crossref_primary_10_1016_j_jtho_2019_01_004 crossref_primary_10_1016_j_lungcan_2021_02_014 crossref_primary_10_1186_s12957_024_03434_1 crossref_primary_10_53876_001c_32276 crossref_primary_10_12677_ACM_2023_133480 crossref_primary_10_3390_curroncol29090487 |
| Cites_doi | 10.1186/s13019-017-0614-4 10.1093/annonc/mdx222 10.1093/annonc/mdx308 10.1097/JTO.0b013e3182774108 10.1002/1097-0142(19931201)72:11<3227::AID-CNCR2820721116>3.0.CO;2-C 10.1016/S0140-6736(13)62159-5 10.1016/S1470-2045(17)30691-5 10.1038/nm.3519 10.1016/j.lungcan.2013.06.007 10.1016/S0140-6736(55)92787-2 10.1038/nrclinonc.2016.35 10.1200/JCO.2018.36.15_suppl.8532 10.1016/j.cllc.2012.03.008 10.1158/2159-8290.CD-17-0716 10.1016/S1470-2045(08)70156-6 10.1371/journal.pone.0148659 10.1038/srep33519 10.1016/j.jtho.2016.06.017 10.1002/sim.4780080407 10.1200/JCO.2003.11.040 10.1200/JCO.2005.05.303 10.1200/JCO.2010.33.7089 10.1158/1078-0432.CCR-05-0510 10.1016/j.jtho.2015.10.008 10.1097/JTO.0000000000000559 10.1158/1078-0432.CCR-10-2102 10.1016/S1470-2045(17)30729-5 10.2967/jnumed.108.057307 10.1016/S0022-5223(19)42513-0 10.1200/JCO.2006.08.2826 10.1200/JCO.2018.36.15_suppl.8541 10.1056/NEJMoa1801005 10.1200/JCO.1993.11.9.1757 10.1158/1078-0432.CCR-14-1268 10.1200/JCO.2009.27.6204 10.1089/cmb.2017.0153 10.1002/cpt.810 10.1200/JCO.2009.26.1685 10.1200/JCO.2015.62.6812 10.1200/JCO.2002.20.3.776 10.1016/S0140-6736(15)60294-X 10.1016/j.ejca.2008.10.026 10.1097/JTO.0b013e31829923ec 10.1016/S1470-2045(11)70336-9 10.1016/S1470-2045(13)70334-6 10.1016/0003-4975(89)90115-X 10.1016/j.lungcan.2008.05.024 10.1016/j.cllc.2013.03.006 10.1097/JTO.0b013e318247504a 10.1158/1078-0432.CCR-17-3628 10.7326/0003-4819-151-4-200908180-00132 10.1002/ijc.25819 10.1158/1078-0432.CCR-17-2289 10.1093/jnci/86.9.673 10.1056/NEJM199401203300301 10.1097/SLA.0b013e31822a7047 10.1056/NEJMoa1716078 10.1097/JTO.0000000000000673 10.1200/JCO.2018.78.8604 10.1093/annonc/mdy218 10.1002/1097-0142(19850315)55:6<1226::AID-CNCR2820550614>3.0.CO;2-6 10.1200/JCO.2007.15.0235 10.1158/2159-8290.CD-16-0577 10.1016/j.jtho.2015.12.104 10.1200/JCO.2015.65.5167 10.1038/nature22364 10.1093/jnci/djm287 10.1097/JTO.0b013e31824c7d92 10.1200/JCO.2002.08.092 10.1097/JTO.0000000000000678 10.1016/j.athoracsur.2004.06.102 10.1378/chest.120.5.1584 10.1016/S0140-6736(13)62422-8 10.1016/j.jtho.2017.12.001 10.1001/jama.2014.3741 10.1158/1078-0432.CCR-13-1212 10.1056/NEJMoa1606774 |
| ContentType | Journal Article |
| Copyright | 2018 Copyright © 2018 by the International Association for the Study of Lung Cancer Published by Elsevier Inc. |
| Copyright_xml | – notice: 2018 – notice: Copyright © 2018 by the International Association for the Study of Lung Cancer – notice: Published by Elsevier Inc. |
| DBID | 6I. AAFTH AAYXX CITATION NPM 7X8 ADTPV AOWAS D8T ZZAVC |
| DOI | 10.1016/j.jtho.2018.09.017 |
| DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access CrossRef PubMed MEDLINE - Academic SwePub SwePub Articles SWEPUB Freely available online SwePub Articles full text |
| DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
| DatabaseTitleList | PubMed MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1556-1380 |
| EndPage | 1831 |
| ExternalDocumentID | oai_swepub_ki_se_485248 30268698 10_1016_j_jtho_2018_09_017 01243894-201812000-00005 S1556086418331290 |
| Genre | Journal Article Review |
| GrantInformation_xml | – fundername: NCI NIH HHS grantid: P30 CA008748 |
| GroupedDBID | --- .55 .XZ .Z2 0R~ 457 53G 5GY 5VS 6I. 9UZ AACTN AAEDW AAFTH AAIAV AAKAS AALRI AAWTL AAXUO ABBUW ABJNI ABMAC ABPMR ABVKL ACDDN ACGFS ACWDW ACWRI ADBBV ADBIZ ADEZE ADZCM AE3 AENEX AEXQZ AFTJW AFTRI AGHFR AHPSJ AITUG AIZYK ALMA_UNASSIGNED_HOLDINGS AMRAJ AWKKM BOYCO C45 CS3 DU5 E.X EBS EJD EX3 F5P FDB FL- HZ~ IN~ KD2 NCXOZ NTWIH O9- OFXIZ OGEVE OK1 OVD P2P ROL S4S SSZ TEORI V2I W3M WOQ WOW X7M AAYWO ADVLN AFETI AFJKZ AGCQF AKRWK APXCP AAYXX ACVFH ADCNI AEUPX AFPUW AIGII AKBMS AKYEP CITATION NPM 7X8 EFKBS ADTPV AOWAS D8T ZZAVC |
| ID | FETCH-LOGICAL-c5495-edcb1b96a421408b200ddd349751b718eddadeac1794ff2be33640324275205a3 |
| ISSN | 1556-0864 1556-1380 |
| IngestDate | Mon Sep 01 03:30:41 EDT 2025 Thu Sep 04 18:52:09 EDT 2025 Thu Apr 03 07:07:04 EDT 2025 Tue Jul 01 02:56:43 EDT 2025 Thu Apr 24 23:00:21 EDT 2025 Fri May 16 03:42:14 EDT 2025 Fri Feb 23 02:49:04 EST 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 12 |
| Keywords | Neoadjuvant therapy Resectable lung cancer Induction chemotherapy Preoperative therapy Pathologic response |
| Language | English |
| License | This article is made available under the Elsevier license. Published by Elsevier Inc. |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c5495-edcb1b96a421408b200ddd349751b718eddadeac1794ff2be33640324275205a3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 |
| OpenAccessLink | http://kipublications.ki.se/Default.aspx?queryparsed=id:139661769 |
| PMID | 30268698 |
| PQID | 2115274261 |
| PQPubID | 23479 |
| PageCount | 14 |
| ParticipantIDs | swepub_primary_oai_swepub_ki_se_485248 proquest_miscellaneous_2115274261 pubmed_primary_30268698 crossref_citationtrail_10_1016_j_jtho_2018_09_017 crossref_primary_10_1016_j_jtho_2018_09_017 wolterskluwer_health_01243894-201812000-00005 elsevier_sciencedirect_doi_10_1016_j_jtho_2018_09_017 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2018-December |
| PublicationDateYYYYMMDD | 2018-12-01 |
| PublicationDate_xml | – month: 12 year: 2018 text: 2018-December |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Journal of thoracic oncology |
| PublicationTitleAlternate | J Thorac Oncol |
| PublicationYear | 2018 |
| Publisher | Elsevier Inc Copyright by the International Association for the Study of Lung Cancer |
| Publisher_xml | – name: Elsevier Inc – name: Copyright by the International Association for the Study of Lung Cancer |
| References | Cerfolio, Bryant, Winokur (bib52) 2004; 78 Crosbie, Shah, Krysiak (bib65) 2016; 11 Newman, Bratman, To (bib70) 2014; 20 (bib46) 2014; 383 Bacci, Picci, Ferrari (bib10) 1993; 72 Cottrell, Thompson, Forde (bib61) 2018; 29 Cortazar, Zhang, Untch (bib8) 2014; 384 Maziak, Darling, Inculet (bib49) 2009; 151 Accessed November 1, 2018. Depierre, Milleron, Moro-Sibilot (bib47) 2002; 20 William, Pataer, Kalhor (bib48) 2013; 8 Horn, Keedy, Campbell (bib82) 2013; 14 Mishra, Daescu, Leavey, Rakheja, Sengupta (bib11) 2018; 25 Chaft, Dunphy, Naidoo (bib19) 2016; 11 Blumenthal, Scher, Cortazar (bib76) 2013; 19 Postmus, Kerr, Oudkerk (bib28) 2017; 28 Rosell, Gomez-Codina, Camps (bib14) 1994; 330 Eberhardt, Pottgen, Gauler (bib54) 2015; 33 Curigliano, Burstein, E PW (bib79) 2017; 28 Pisters, Vallieres, Crowley (bib16) 2010; 28 Rami-Porta, Bolejack, Crowley (bib3) 2015; 10 Abbosh, Birkbak, Wilson (bib69) 2017; 545 Pottgen, Levegrun, Theegarten (bib56) 2006; 12 Yie, Lou, Ye (bib68) 2009; 63 Wakelee, Dahlberg, Keller (bib22) 2017; 18 Martin, Ginsberg, Venkatraman (bib30) 2002; 20 Lindeman, Cagle, Aisner (bib62) 2018; 13 Rastogi, Anderson, Bear (bib6) 2008; 26 Pottgen, Gauler, Bellendorf (bib55) 2016; 34 Singh, Walker, Amiri-Kordestani (bib4) 2018; 24 Roth, Fossella, Komaki (bib15) 1994; 86 Felip, Rosell, Maestre (bib17) 2010; 28 Zhong, Wang, Mao (bib39) 2018; 19 National Comprehensive Cancer Network. 2018. Chaft, Rusch, Ginsberg (bib57) 2013; 8 Rusch, Chaft, Johnson (bib35) 2018; 36 Nicholson, Chansky, Crowley (bib83) 2016; 11 Chaudhuri, Chabon, Lovejoy (bib63) 2017; 7 Francis, Crown, Di Leo (bib7) 2008; 100 Crosbie, Shah, Summers (bib66) 2013; 2 Hilaris, Gomez, Nori (bib12) 1985; 55 Horita, Miyazawa, Morita (bib80) 2013; 14 U.S. Department of Health and Human Services, FDA, Center for Drug Evaluation and Research (CDER). Guidance for Industry Pathological Complete Response in Neoadjuvant Treatment of High-Risk Early-Stage Breast Cancer: Use as an Endpoint to Support Accelerated Approval. 2014. Faber, Kittle, Warren (bib13) 1989; 47 Shu, Grigg, Chiuzan (bib37) 2018; 36 Prentice (bib73) 1989; 8 De Mattos-Arruda, Shen, Reis-Filho (bib23) 2016; 13 Denduluri, Chavez-MacGregor, Telli (bib5) 2018 Eisenhauer, Therasse, Bogaerts (bib45) 2009; 45 Amiri-Kordestani, Wedam, Zhang (bib75) 2014; 20 Eberhardt, Mitchell, Crowley (bib1) 2015; 10 Bielack, Kempf-Bielack, Delling (bib9) 2002; 20 Wahl, Jacene, Kasamon (bib50) 2009; 50 Hofman, Ilie, Long (bib67) 2011; 129 Mouillet, Monnet, Milleron (bib78) 2012; 7 Forde, Chaft, Smith (bib34) 2018; 378 Gianni, Pienkowski, Im (bib20) 2012; 13 Junker, Langner, Klinke (bib58) 2001; 120 Pataer, Kalhor, Correa (bib59) 2012; 7 Pless, Stupp, Ris (bib31) 2015; 386 Bayarri-Lara, Ortega, Cueto Ladron de Guevara (bib64) 2016; 11 Guo, Lou, Ma (bib42) 2016; 6 Hellmann, Chaft, William (bib60) 2014; 15 Asamura, Chansky, Crowley (bib2) 2015; 10 Betticher, Hsu Schmitz, Totsch (bib51) 2003; 21 Pisters, Kris, Gralla (bib77) 1993; 11 Shields, Higgins, Lawton (bib26) 1970; 59 Al-Refaie, Vickers, Zhong (bib81) 2011; 254 Scagliotti, Pastorino, Vansteenkiste (bib18) 2012; 30 Aisner, Sholl, Berry (bib44) 2018; 24 Rizvi, Rusch, Pao (bib40) 2011; 17 Tie, Cohen, Wang (bib71) 2018 Gandhi, Rodriguez-Abreu, Gadgeel (bib33) 2018; 378 Burdett, Stewart, Auperin (bib24) 2005; 23 Mayekar, Bivona (bib38) 2017; 102 Eberhardt, Gauler, Lepechoux (bib53) 2013; 82 U.S. Department of Health and Human Services, FDA, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). Guidance for Industry Expedited Programs for Serious Conditions – Drugs and Biologics 2014. Bromley, Szur (bib25) 1955; 269 Reck, Rodriguez-Abreu, Robinson (bib32) 2016; 375 Lugg, Tikka, Agostini (bib21) 2017; 12 Rusch, Giroux, Kraut (bib27) 2007; 25 Thomas, Rube, Hoffknecht (bib29) 2008; 9 Liu, Blake, Yong (bib36) 2016; 6 Kris, Johnson, Berry (bib43) 2014; 311 Aisner (10.1016/j.jtho.2018.09.017_bib44) 2018; 24 De Mattos-Arruda (10.1016/j.jtho.2018.09.017_bib23) 2016; 13 Maziak (10.1016/j.jtho.2018.09.017_bib49) 2009; 151 Faber (10.1016/j.jtho.2018.09.017_bib13) 1989; 47 Cerfolio (10.1016/j.jtho.2018.09.017_bib52) 2004; 78 Rastogi (10.1016/j.jtho.2018.09.017_bib6) 2008; 26 Pottgen (10.1016/j.jtho.2018.09.017_bib55) 2016; 34 Reck (10.1016/j.jtho.2018.09.017_bib32) 2016; 375 Hilaris (10.1016/j.jtho.2018.09.017_bib12) 1985; 55 Rizvi (10.1016/j.jtho.2018.09.017_bib40) 2011; 17 Felip (10.1016/j.jtho.2018.09.017_bib17) 2010; 28 Tie (10.1016/j.jtho.2018.09.017_bib71) 2018 Depierre (10.1016/j.jtho.2018.09.017_bib47) 2002; 20 Hellmann (10.1016/j.jtho.2018.09.017_bib60) 2014; 15 Crosbie (10.1016/j.jtho.2018.09.017_bib65) 2016; 11 Eberhardt (10.1016/j.jtho.2018.09.017_bib54) 2015; 33 Mouillet (10.1016/j.jtho.2018.09.017_bib78) 2012; 7 Bayarri-Lara (10.1016/j.jtho.2018.09.017_bib64) 2016; 11 Horita (10.1016/j.jtho.2018.09.017_bib80) 2013; 14 Mishra (10.1016/j.jtho.2018.09.017_bib11) 2018; 25 Thomas (10.1016/j.jtho.2018.09.017_bib29) 2008; 9 Mayekar (10.1016/j.jtho.2018.09.017_bib38) 2017; 102 Cottrell (10.1016/j.jtho.2018.09.017_bib61) 2018; 29 Zhong (10.1016/j.jtho.2018.09.017_bib39) 2018; 19 Singh (10.1016/j.jtho.2018.09.017_bib4) 2018; 24 Betticher (10.1016/j.jtho.2018.09.017_bib51) 2003; 21 Bielack (10.1016/j.jtho.2018.09.017_bib9) 2002; 20 Kris (10.1016/j.jtho.2018.09.017_bib43) 2014; 311 Chaft (10.1016/j.jtho.2018.09.017_bib57) 2013; 8 Pisters (10.1016/j.jtho.2018.09.017_bib77) 1993; 11 Chaft (10.1016/j.jtho.2018.09.017_bib19) 2016; 11 10.1016/j.jtho.2018.09.017_bib72 10.1016/j.jtho.2018.09.017_bib74 Shields (10.1016/j.jtho.2018.09.017_bib26) 1970; 59 Al-Refaie (10.1016/j.jtho.2018.09.017_bib81) 2011; 254 Eberhardt (10.1016/j.jtho.2018.09.017_bib1) 2015; 10 Forde (10.1016/j.jtho.2018.09.017_bib34) 2018; 378 Nicholson (10.1016/j.jtho.2018.09.017_bib83) 2016; 11 Rusch (10.1016/j.jtho.2018.09.017_bib35) 2018; 36 Shu (10.1016/j.jtho.2018.09.017_bib37) 2018; 36 Wakelee (10.1016/j.jtho.2018.09.017_bib22) 2017; 18 Wahl (10.1016/j.jtho.2018.09.017_bib50) 2009; 50 Chaudhuri (10.1016/j.jtho.2018.09.017_bib63) 2017; 7 Bacci (10.1016/j.jtho.2018.09.017_bib10) 1993; 72 William (10.1016/j.jtho.2018.09.017_bib48) 2013; 8 Roth (10.1016/j.jtho.2018.09.017_bib15) 1994; 86 Eberhardt (10.1016/j.jtho.2018.09.017_bib53) 2013; 82 Martin (10.1016/j.jtho.2018.09.017_bib30) 2002; 20 Eisenhauer (10.1016/j.jtho.2018.09.017_bib45) 2009; 45 Newman (10.1016/j.jtho.2018.09.017_bib70) 2014; 20 Rosell (10.1016/j.jtho.2018.09.017_bib14) 1994; 330 Burdett (10.1016/j.jtho.2018.09.017_bib24) 2005; 23 Yie (10.1016/j.jtho.2018.09.017_bib68) 2009; 63 Bromley (10.1016/j.jtho.2018.09.017_bib25) 1955; 269 Rusch (10.1016/j.jtho.2018.09.017_bib27) 2007; 25 Francis (10.1016/j.jtho.2018.09.017_bib7) 2008; 100 Hofman (10.1016/j.jtho.2018.09.017_bib67) 2011; 129 Gianni (10.1016/j.jtho.2018.09.017_bib20) 2012; 13 Blumenthal (10.1016/j.jtho.2018.09.017_bib76) 2013; 19 Asamura (10.1016/j.jtho.2018.09.017_bib2) 2015; 10 Amiri-Kordestani (10.1016/j.jtho.2018.09.017_bib75) 2014; 20 Lugg (10.1016/j.jtho.2018.09.017_bib21) 2017; 12 10.1016/j.jtho.2018.09.017_bib41 Scagliotti (10.1016/j.jtho.2018.09.017_bib18) 2012; 30 Denduluri (10.1016/j.jtho.2018.09.017_bib5) 2018 Prentice (10.1016/j.jtho.2018.09.017_bib73) 1989; 8 Liu (10.1016/j.jtho.2018.09.017_bib36) 2016; 6 Pataer (10.1016/j.jtho.2018.09.017_bib59) 2012; 7 Abbosh (10.1016/j.jtho.2018.09.017_bib69) 2017; 545 Curigliano (10.1016/j.jtho.2018.09.017_bib79) 2017; 28 Postmus (10.1016/j.jtho.2018.09.017_bib28) 2017; 28 Cortazar (10.1016/j.jtho.2018.09.017_bib8) 2014; 384 Guo (10.1016/j.jtho.2018.09.017_bib42) 2016; 6 Pisters (10.1016/j.jtho.2018.09.017_bib16) 2010; 28 Junker (10.1016/j.jtho.2018.09.017_bib58) 2001; 120 Lindeman (10.1016/j.jtho.2018.09.017_bib62) 2018; 13 Pless (10.1016/j.jtho.2018.09.017_bib31) 2015; 386 Gandhi (10.1016/j.jtho.2018.09.017_bib33) 2018; 378 Pottgen (10.1016/j.jtho.2018.09.017_bib56) 2006; 12 Horn (10.1016/j.jtho.2018.09.017_bib82) 2013; 14 (10.1016/j.jtho.2018.09.017_bib46) 2014; 383 Rami-Porta (10.1016/j.jtho.2018.09.017_bib3) 2015; 10 Crosbie (10.1016/j.jtho.2018.09.017_bib66) 2013; 2 |
| References_xml | – volume: 14 start-page: 14 year: 2013 end-page: 18 ident: bib82 article-title: Identifying barriers associated with enrollment of patients with lung cancer into clinical trials publication-title: Clin Lung Cancer – volume: 20 start-page: 776 year: 2002 end-page: 790 ident: bib9 article-title: Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols publication-title: J Clin Oncol – volume: 7 start-page: 825 year: 2012 end-page: 832 ident: bib59 article-title: Histopathologic response criteria predict survival of patients with resected lung cancer after neoadjuvant chemotherapy publication-title: J Thorac Oncol – volume: 21 start-page: 1752 year: 2003 end-page: 1759 ident: bib51 article-title: Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non–small-cell lung cancer: a multicenter phase II trial publication-title: J Clin Oncol – volume: 19 start-page: 139 year: 2018 end-page: 148 ident: bib39 article-title: Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study publication-title: Lancet Oncol – volume: 383 start-page: 1561 year: 2014 end-page: 1571 ident: bib46 article-title: Preoperative chemotherapy for non–small-cell lung cancer: a systematic review and meta-analysis of individual participant data publication-title: Lancet – volume: 7 start-page: 841 year: 2012 end-page: 849 ident: bib78 article-title: Pathologic complete response to preoperative chemotherapy predicts cure in early-stage non-small-cell lung cancer: combined analysis of two IFCT randomized trials publication-title: J Thorac Oncol – volume: 24 start-page: 3486 year: 2018 end-page: 3491 ident: bib4 article-title: U.S. Food and Drug Administration approval: neratinib for the extended adjuvant treatment of early-stage HER2-positive breast cancer publication-title: Clin Cancer Res – volume: 378 start-page: 1976 year: 2018 end-page: 1986 ident: bib34 article-title: Neoadjuvant PD-1 blockade in resectable lung cancer publication-title: N Engl J Med – volume: 28 start-page: 1843 year: 2010 end-page: 1849 ident: bib16 article-title: Surgery with or without preoperative paclitaxel and carboplatin in early-stage non–small-cell lung cancer: Southwest Oncology Group Trial S9900, an intergroup, randomized, phase III trial publication-title: J Clin Oncol – volume: 545 start-page: 446 year: 2017 end-page: 451 ident: bib69 article-title: Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution publication-title: Nature – volume: 17 start-page: 3500 year: 2011 end-page: 3506 ident: bib40 article-title: Molecular characteristics predict clinical outcomes: prospective trial correlating response to the EGFR tyrosine kinase inhibitor gefitinib with the presence of sensitizing mutations in the tyrosine binding domain of the EGFR gene publication-title: Clin Cancer Res – volume: 25 start-page: 313 year: 2018 end-page: 325 ident: bib11 article-title: Convolutional neural network for histopathological analysis of osteosarcoma publication-title: J Comput Biol – volume: 10 start-page: 1515 year: 2015 end-page: 1522 ident: bib1 article-title: The IASLC Lung Cancer Staging Project: proposals for the revision of the M descriptors in the forthcoming eighth edition of the TNM classification of lung cancer publication-title: J Thorac Oncol – volume: 30 start-page: 172 year: 2012 end-page: 178 ident: bib18 article-title: Randomized phase III study of surgery alone or surgery plus preoperative cisplatin and gemcitabine in stages IB to IIIA non–small-cell lung cancer publication-title: J Clin Oncol – volume: 13 start-page: 25 year: 2012 end-page: 32 ident: bib20 article-title: Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial publication-title: Lancet Oncol – volume: 102 start-page: 757 year: 2017 end-page: 764 ident: bib38 article-title: Current landscape of targeted therapy in lung cancer publication-title: Clin Pharmacol Ther – volume: 129 start-page: 1651 year: 2011 end-page: 1660 ident: bib67 article-title: Detection of circulating tumor cells as a prognostic factor in patients undergoing radical surgery for non–small-cell lung carcinoma: comparison of the efficacy of the CellSearch Assay and the isolation by size of epithelial tumor cell method publication-title: Int J Cancer – year: 2018 ident: bib5 article-title: Selection of optimal adjuvant chemotherapy and targeted therapy for early breast cancer: ASCO clinical practice guideline focused update publication-title: J Clin Oncol – volume: 11 start-page: 1793 year: 2016 end-page: 1797 ident: bib65 article-title: Circulating tumor cells detected in the tumor-draining pulmonary vein are associated with disease recurrence after surgical resection of NSCLC publication-title: J Thorac Oncol – volume: 13 start-page: 323 year: 2018 end-page: 358 ident: bib62 article-title: Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: guideline from the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology publication-title: J Thorac Oncol – volume: 20 start-page: 1989 year: 2002 end-page: 1995 ident: bib30 article-title: Long-term results of combined-modality therapy in resectable non–small-cell lung cancer publication-title: J Clin Oncol – volume: 8 start-page: 1084 year: 2013 end-page: 1090 ident: bib57 article-title: Phase II trial of neoadjuvant bevacizumab plus chemotherapy and adjuvant bevacizumab in patients with resectable nonsquamous non-small-cell lung cancers publication-title: J Thorac Oncol – volume: 25 start-page: 313 year: 2007 end-page: 318 ident: bib27 article-title: Induction chemoradiation and surgical resection for superior sulcus non–small-cell lung carcinomas: long-term results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160) publication-title: J Clin Oncol – volume: 8 start-page: 222 year: 2013 end-page: 228 ident: bib48 article-title: Computed tomography RECIST assessment of histopathologic response and prediction of survival in patients with resectable non–small-cell lung cancer after neoadjuvant chemotherapy publication-title: J Thorac Oncol – volume: 63 start-page: 284 year: 2009 end-page: 290 ident: bib68 article-title: Clinical significance of detecting survivin-expressing circulating cancer cells in patients with non–small cell lung cancer publication-title: Lung Cancer – volume: 28 start-page: iv1 year: 2017 end-page: iv21 ident: bib28 article-title: Early and locally advanced non–small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up publication-title: Ann Oncol – volume: 378 start-page: 2078 year: 2018 end-page: 2092 ident: bib33 article-title: Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer publication-title: N Engl J Med – volume: 28 start-page: 3138 year: 2010 end-page: 3145 ident: bib17 article-title: Preoperative chemotherapy plus surgery versus surgery plus adjuvant chemotherapy versus surgery alone in early-stage non–small-cell lung cancer publication-title: J Clin Oncol – volume: 254 start-page: 438 year: 2011 end-page: 443 ident: bib81 article-title: Cancer trials versus the real world in the United States publication-title: Ann Surg – volume: 12 start-page: 97 year: 2006 end-page: 106 ident: bib56 article-title: Value of 18F-fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in non–small-cell lung cancer for prediction of pathologic response and times to relapse after neoadjuvant chemoradiotherapy publication-title: Clin Cancer Res – volume: 50 start-page: 122S year: 2009 end-page: 150S ident: bib50 article-title: From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors publication-title: J Nucl Med – volume: 11 start-page: 1757 year: 1993 end-page: 1762 ident: bib77 article-title: Pathologic complete response in advanced non–small-cell lung cancer following preoperative chemotherapy: implications for the design of future non-small-cell lung cancer combined modality trials publication-title: J Clin Oncol – volume: 151 start-page: 221 year: 2009 end-page: 228 ident: bib49 article-title: Positron emission tomography in staging early lung cancer: a randomized trial publication-title: Ann Intern Med – volume: 20 start-page: 548 year: 2014 end-page: 554 ident: bib70 article-title: An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage publication-title: Nat Med – volume: 13 start-page: 566 year: 2016 end-page: 579 ident: bib23 article-title: Translating neoadjuvant therapy into survival benefits: one size does not fit all publication-title: Nat Rev Clin Oncol – volume: 9 start-page: 636 year: 2008 end-page: 648 ident: bib29 article-title: Effect of preoperative chemoradiation in addition to preoperative chemotherapy: a randomised trial in stage III non–small-cell lung cancer publication-title: Lancet Oncol – volume: 24 start-page: 1038 year: 2018 end-page: 1047 ident: bib44 article-title: The impact of smoking and TP53 mutations in lung adenocarcinoma patients with targetable mutations — the Lung Cancer Mutation Consortium (LCMC2) publication-title: Clin Cancer Res – volume: 384 start-page: 164 year: 2014 end-page: 172 ident: bib8 article-title: Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis publication-title: Lancet – volume: 19 start-page: 4911 year: 2013 end-page: 4916 ident: bib76 article-title: First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer publication-title: Clin Cancer Res – volume: 28 start-page: 1700 year: 2017 end-page: 1712 ident: bib79 article-title: De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017 publication-title: Ann Oncol – volume: 11 start-page: 300 year: 2016 end-page: 311 ident: bib83 article-title: The International Association for the Study of Lung Cancer Lung Cancer Staging Project: proposals for the revision of the clinical and pathologic staging of small cell lung cancer in the forthcoming eighth edition of the TNM classification for lung cancer publication-title: J Thorac Oncol – volume: 120 start-page: 1584 year: 2001 end-page: 1591 ident: bib58 article-title: Grading of tumor regression in non–small cell lung cancer: morphology and prognosis publication-title: Chest – volume: 6 start-page: 33519 year: 2016 ident: bib42 article-title: Circulating tumor DNA detection in lung cancer patients before and after surgery publication-title: Sci Rep – volume: 11 start-page: e0148659 year: 2016 ident: bib64 article-title: Circulating tumor cells identify early recurrence in patients with non–small cell lung cancer undergoing radical resection publication-title: PLoS One – volume: 47 start-page: 669 year: 1989 end-page: 675 ident: bib13 article-title: Preoperative chemotherapy and irradiation for stage III non–small cell lung cancer publication-title: Ann Thorac Surg – volume: 8 start-page: 431 year: 1989 end-page: 440 ident: bib73 article-title: Surrogate endpoints in clinical trials: definition and operational criteria publication-title: Stat Med – volume: 59 start-page: 49 year: 1970 end-page: 61 ident: bib26 article-title: Preoperative x-ray therapy as an adjuvant in the treatment of bronchogenic carcinoma publication-title: J Thorac Cardiovasc Surg – volume: 23 start-page: 924 year: 2005 end-page: 925 ident: bib24 article-title: Chemotherapy in non–small-cell lung cancer: an update of an individual patient data meta-analysis publication-title: J Clin Oncol – volume: 36 start-page: 8532 year: 2018 ident: bib37 article-title: Neoadjuvant atezolizumab + chemotherapy in resectable non-small cell lung cancer (NSCLC) publication-title: J Clin Oncol – volume: 82 start-page: 83 year: 2013 end-page: 89 ident: bib53 article-title: 10-year long-term survival (LTS) of induction chemotherapy with three cycles cisplatin/paclitaxel followed by concurrent chemoradiation cisplatin/etoposide/45 Gy (1.5 Gy bid) plus surgery in locally advanced non–small-cell lung cancer (NSCLC)-a multicenter phase-II trial (CISTAXOL) publication-title: Lung Cancer – volume: 15 start-page: e42 year: 2014 end-page: e50 ident: bib60 article-title: Pathological response after neoadjuvant chemotherapy in resectable non–small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint publication-title: Lancet Oncol – volume: 14 start-page: 488 year: 2013 end-page: 494 ident: bib80 article-title: Preoperative chemotherapy is effective for stage III resectable non–small-cell lung cancer: metaanalysis of 16 trials publication-title: Clin Lung Cancer – volume: 18 start-page: 1610 year: 2017 end-page: 1623 ident: bib22 article-title: Adjuvant chemotherapy with or without bevacizumab in patients with resected non–small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial publication-title: Lancet Oncol – volume: 311 start-page: 1998 year: 2014 end-page: 2006 ident: bib43 article-title: Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs publication-title: JAMA – volume: 72 start-page: 3227 year: 1993 end-page: 3238 ident: bib10 article-title: Primary chemotherapy and delayed surgery for nonmetastatic osteosarcoma of the extremities. Results in 164 patients preoperatively treated with high doses of methotrexate followed by cisplatin and doxorubicin publication-title: Cancer – volume: 45 start-page: 228 year: 2009 end-page: 247 ident: bib45 article-title: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) publication-title: Eur J Cancer – volume: 2 start-page: 382 year: 2013 end-page: 397 ident: bib66 article-title: Prognostic and predictive biomarkers in early stage NSCLC: CTCs and serum/plasma markers publication-title: Transl Lung Cancer Res – volume: 375 start-page: 1823 year: 2016 end-page: 1833 ident: bib32 article-title: Pembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung cancer publication-title: N Engl J Med – volume: 20 start-page: 247 year: 2002 end-page: 253 ident: bib47 article-title: Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa non-small-cell lung cancer publication-title: J Clin Oncol – volume: 55 start-page: 1226 year: 1985 end-page: 1231 ident: bib12 article-title: Combined surgery, intraoperative brachytherapy, and postoperative external radiation in stage III non–small cell lung cancer publication-title: Cancer – reference: . Accessed November 1, 2018. – volume: 29 start-page: 1853 year: 2018 end-page: 1860 ident: bib61 article-title: Pathologic features of response to neoadjuvant anti–PD-1 in resected non–small cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC) publication-title: Ann Oncol – year: 2018 ident: bib71 article-title: Serial circulating tumour DNA analysis during multimodality treatment of locally advanced rectal cancer: a prospective biomarker study publication-title: Gut – volume: 10 start-page: 990 year: 2015 end-page: 1003 ident: bib3 article-title: The IASLC Lung Cancer Staging Project: proposals for the revisions of the T descriptors in the forthcoming eighth edition of the TNM classification for lung cancer publication-title: J Thorac Oncol – volume: 12 start-page: 52 year: 2017 ident: bib21 article-title: Smoking and timing of cessation on postoperative pulmonary complications after curative-intent lung cancer surgery publication-title: J Cardiothorac Surg – volume: 386 start-page: 1049 year: 2015 end-page: 1056 ident: bib31 article-title: Induction chemoradiation in stage IIIA/N2 non–small-cell lung cancer: a phase 3 randomised trial publication-title: Lancet – volume: 10 start-page: 1675 year: 2015 end-page: 1684 ident: bib2 article-title: The International Association for the Study of Lung Cancer Lung Cancer Staging Project: proposals for the revision of the N descriptors in the forthcoming 8th edition of the TNM classification for lung cancer publication-title: J Thorac Oncol – reference: U.S. Department of Health and Human Services, FDA, Center for Drug Evaluation and Research (CDER). Guidance for Industry Pathological Complete Response in Neoadjuvant Treatment of High-Risk Early-Stage Breast Cancer: Use as an Endpoint to Support Accelerated Approval. 2014. – volume: 269 start-page: 937 year: 1955 end-page: 941 ident: bib25 article-title: Combined radiotherapy and resection for carcinoma of the bronchus; experiences with 66 patients publication-title: Lancet – volume: 20 start-page: 5359 year: 2014 end-page: 5364 ident: bib75 article-title: First FDA approval of neoadjuvant therapy for breast cancer: pertuzumab for the treatment of patients with HER2-positive breast cancer publication-title: Clin Cancer Res – volume: 36 start-page: 8541 year: 2018 ident: bib35 article-title: Neoadjuvant atezolizumab in resectable non-small cell lung cancer (NSCLC): Initial results from a multicenter study (LCMC3) publication-title: J Clin Oncol – volume: 7 start-page: 1394 year: 2017 end-page: 1403 ident: bib63 article-title: Early detection of molecular residual disease in localized lung cancer by circulating tumor DNA profiling publication-title: Cancer Discov – volume: 26 start-page: 778 year: 2008 end-page: 785 ident: bib6 article-title: Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27 publication-title: J Clin Oncol – volume: 330 start-page: 153 year: 1994 end-page: 158 ident: bib14 article-title: A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer publication-title: N Engl J Med – volume: 11 start-page: 537 year: 2016 end-page: 544 ident: bib19 article-title: Adaptive neoadjuvant chemotherapy guided by (18)F-FDG PET in resectable non–small cell lung cancers: the NEOSCAN trial publication-title: J Thorac Oncol – volume: 33 start-page: 4194 year: 2015 end-page: 4201 ident: bib54 article-title: Phase III study of surgery versus definitive concurrent chemoradiotherapy boost in patients with resectable stage IIIA(N2) and selected IIIB non–small-cell lung cancer after induction chemotherapy and concurrent chemoradiotherapy (ESPATUE) publication-title: J Clin Oncol – reference: U.S. Department of Health and Human Services, FDA, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). Guidance for Industry Expedited Programs for Serious Conditions – Drugs and Biologics 2014. – volume: 100 start-page: 121 year: 2008 end-page: 133 ident: bib7 article-title: Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial publication-title: J Natl Cancer Inst – volume: 6 start-page: 1382 year: 2016 end-page: 1399 ident: bib36 article-title: Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease publication-title: Cancer Discov – reference: National Comprehensive Cancer Network. 2018. – volume: 86 start-page: 673 year: 1994 end-page: 680 ident: bib15 article-title: A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non–small-cell lung cancer publication-title: J Natl Cancer Inst – volume: 34 start-page: 2526 year: 2016 end-page: 2533 ident: bib55 article-title: Standardized uptake decrease on [18F]-fluorodeoxyglucose positron emission tomography after neoadjuvant chemotherapy is a prognostic classifier for long-term outcome after multimodality treatment: secondary analysis of a randomized trial for resectable stage IIIA/B non–small-cell lung cancer publication-title: J Clin Oncol – volume: 78 start-page: 1903 year: 2004 end-page: 1909 ident: bib52 article-title: Repeat FDG-PET after neoadjuvant therapy is a predictor of pathologic response in patients with non–small cell lung cancer publication-title: Ann Thorac Surg – volume: 12 start-page: 52 year: 2017 ident: 10.1016/j.jtho.2018.09.017_bib21 article-title: Smoking and timing of cessation on postoperative pulmonary complications after curative-intent lung cancer surgery publication-title: J Cardiothorac Surg doi: 10.1186/s13019-017-0614-4 – volume: 28 start-page: iv1 year: 2017 ident: 10.1016/j.jtho.2018.09.017_bib28 article-title: Early and locally advanced non–small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up publication-title: Ann Oncol doi: 10.1093/annonc/mdx222 – volume: 28 start-page: 1700 year: 2017 ident: 10.1016/j.jtho.2018.09.017_bib79 article-title: De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017 publication-title: Ann Oncol doi: 10.1093/annonc/mdx308 – volume: 8 start-page: 222 year: 2013 ident: 10.1016/j.jtho.2018.09.017_bib48 article-title: Computed tomography RECIST assessment of histopathologic response and prediction of survival in patients with resectable non–small-cell lung cancer after neoadjuvant chemotherapy publication-title: J Thorac Oncol doi: 10.1097/JTO.0b013e3182774108 – volume: 72 start-page: 3227 year: 1993 ident: 10.1016/j.jtho.2018.09.017_bib10 article-title: Primary chemotherapy and delayed surgery for nonmetastatic osteosarcoma of the extremities. Results in 164 patients preoperatively treated with high doses of methotrexate followed by cisplatin and doxorubicin publication-title: Cancer doi: 10.1002/1097-0142(19931201)72:11<3227::AID-CNCR2820721116>3.0.CO;2-C – volume: 383 start-page: 1561 year: 2014 ident: 10.1016/j.jtho.2018.09.017_bib46 article-title: Preoperative chemotherapy for non–small-cell lung cancer: a systematic review and meta-analysis of individual participant data publication-title: Lancet doi: 10.1016/S0140-6736(13)62159-5 – volume: 18 start-page: 1610 year: 2017 ident: 10.1016/j.jtho.2018.09.017_bib22 article-title: Adjuvant chemotherapy with or without bevacizumab in patients with resected non–small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial publication-title: Lancet Oncol doi: 10.1016/S1470-2045(17)30691-5 – ident: 10.1016/j.jtho.2018.09.017_bib41 – volume: 20 start-page: 548 year: 2014 ident: 10.1016/j.jtho.2018.09.017_bib70 article-title: An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage publication-title: Nat Med doi: 10.1038/nm.3519 – volume: 2 start-page: 382 year: 2013 ident: 10.1016/j.jtho.2018.09.017_bib66 article-title: Prognostic and predictive biomarkers in early stage NSCLC: CTCs and serum/plasma markers publication-title: Transl Lung Cancer Res – volume: 82 start-page: 83 year: 2013 ident: 10.1016/j.jtho.2018.09.017_bib53 publication-title: Lung Cancer doi: 10.1016/j.lungcan.2013.06.007 – volume: 269 start-page: 937 year: 1955 ident: 10.1016/j.jtho.2018.09.017_bib25 article-title: Combined radiotherapy and resection for carcinoma of the bronchus; experiences with 66 patients publication-title: Lancet doi: 10.1016/S0140-6736(55)92787-2 – ident: 10.1016/j.jtho.2018.09.017_bib74 – volume: 13 start-page: 566 year: 2016 ident: 10.1016/j.jtho.2018.09.017_bib23 article-title: Translating neoadjuvant therapy into survival benefits: one size does not fit all publication-title: Nat Rev Clin Oncol doi: 10.1038/nrclinonc.2016.35 – volume: 36 start-page: 8532 issue: suppl 15 year: 2018 ident: 10.1016/j.jtho.2018.09.017_bib37 article-title: Neoadjuvant atezolizumab + chemotherapy in resectable non-small cell lung cancer (NSCLC) publication-title: J Clin Oncol doi: 10.1200/JCO.2018.36.15_suppl.8532 – volume: 14 start-page: 14 year: 2013 ident: 10.1016/j.jtho.2018.09.017_bib82 article-title: Identifying barriers associated with enrollment of patients with lung cancer into clinical trials publication-title: Clin Lung Cancer doi: 10.1016/j.cllc.2012.03.008 – volume: 7 start-page: 1394 year: 2017 ident: 10.1016/j.jtho.2018.09.017_bib63 article-title: Early detection of molecular residual disease in localized lung cancer by circulating tumor DNA profiling publication-title: Cancer Discov doi: 10.1158/2159-8290.CD-17-0716 – year: 2018 ident: 10.1016/j.jtho.2018.09.017_bib71 article-title: Serial circulating tumour DNA analysis during multimodality treatment of locally advanced rectal cancer: a prospective biomarker study publication-title: Gut – volume: 9 start-page: 636 year: 2008 ident: 10.1016/j.jtho.2018.09.017_bib29 article-title: Effect of preoperative chemoradiation in addition to preoperative chemotherapy: a randomised trial in stage III non–small-cell lung cancer publication-title: Lancet Oncol doi: 10.1016/S1470-2045(08)70156-6 – volume: 11 start-page: e0148659 year: 2016 ident: 10.1016/j.jtho.2018.09.017_bib64 article-title: Circulating tumor cells identify early recurrence in patients with non–small cell lung cancer undergoing radical resection publication-title: PLoS One doi: 10.1371/journal.pone.0148659 – volume: 6 start-page: 33519 year: 2016 ident: 10.1016/j.jtho.2018.09.017_bib42 article-title: Circulating tumor DNA detection in lung cancer patients before and after surgery publication-title: Sci Rep doi: 10.1038/srep33519 – volume: 11 start-page: 1793 year: 2016 ident: 10.1016/j.jtho.2018.09.017_bib65 article-title: Circulating tumor cells detected in the tumor-draining pulmonary vein are associated with disease recurrence after surgical resection of NSCLC publication-title: J Thorac Oncol doi: 10.1016/j.jtho.2016.06.017 – volume: 8 start-page: 431 year: 1989 ident: 10.1016/j.jtho.2018.09.017_bib73 article-title: Surrogate endpoints in clinical trials: definition and operational criteria publication-title: Stat Med doi: 10.1002/sim.4780080407 – volume: 20 start-page: 247 year: 2002 ident: 10.1016/j.jtho.2018.09.017_bib47 article-title: Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa non-small-cell lung cancer publication-title: J Clin Oncol – volume: 21 start-page: 1752 year: 2003 ident: 10.1016/j.jtho.2018.09.017_bib51 article-title: Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non–small-cell lung cancer: a multicenter phase II trial publication-title: J Clin Oncol doi: 10.1200/JCO.2003.11.040 – volume: 23 start-page: 924 year: 2005 ident: 10.1016/j.jtho.2018.09.017_bib24 article-title: Chemotherapy in non–small-cell lung cancer: an update of an individual patient data meta-analysis publication-title: J Clin Oncol doi: 10.1200/JCO.2005.05.303 – volume: 30 start-page: 172 year: 2012 ident: 10.1016/j.jtho.2018.09.017_bib18 article-title: Randomized phase III study of surgery alone or surgery plus preoperative cisplatin and gemcitabine in stages IB to IIIA non–small-cell lung cancer publication-title: J Clin Oncol doi: 10.1200/JCO.2010.33.7089 – volume: 12 start-page: 97 year: 2006 ident: 10.1016/j.jtho.2018.09.017_bib56 article-title: Value of 18F-fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in non–small-cell lung cancer for prediction of pathologic response and times to relapse after neoadjuvant chemoradiotherapy publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-05-0510 – volume: 11 start-page: 300 year: 2016 ident: 10.1016/j.jtho.2018.09.017_bib83 article-title: The International Association for the Study of Lung Cancer Lung Cancer Staging Project: proposals for the revision of the clinical and pathologic staging of small cell lung cancer in the forthcoming eighth edition of the TNM classification for lung cancer publication-title: J Thorac Oncol doi: 10.1016/j.jtho.2015.10.008 – volume: 10 start-page: 990 year: 2015 ident: 10.1016/j.jtho.2018.09.017_bib3 article-title: The IASLC Lung Cancer Staging Project: proposals for the revisions of the T descriptors in the forthcoming eighth edition of the TNM classification for lung cancer publication-title: J Thorac Oncol doi: 10.1097/JTO.0000000000000559 – volume: 17 start-page: 3500 year: 2011 ident: 10.1016/j.jtho.2018.09.017_bib40 article-title: Molecular characteristics predict clinical outcomes: prospective trial correlating response to the EGFR tyrosine kinase inhibitor gefitinib with the presence of sensitizing mutations in the tyrosine binding domain of the EGFR gene publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-10-2102 – volume: 19 start-page: 139 year: 2018 ident: 10.1016/j.jtho.2018.09.017_bib39 article-title: Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study publication-title: Lancet Oncol doi: 10.1016/S1470-2045(17)30729-5 – volume: 50 start-page: 122S issue: suppl 1 year: 2009 ident: 10.1016/j.jtho.2018.09.017_bib50 article-title: From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors publication-title: J Nucl Med doi: 10.2967/jnumed.108.057307 – volume: 59 start-page: 49 year: 1970 ident: 10.1016/j.jtho.2018.09.017_bib26 article-title: Preoperative x-ray therapy as an adjuvant in the treatment of bronchogenic carcinoma publication-title: J Thorac Cardiovasc Surg doi: 10.1016/S0022-5223(19)42513-0 – volume: 25 start-page: 313 year: 2007 ident: 10.1016/j.jtho.2018.09.017_bib27 article-title: Induction chemoradiation and surgical resection for superior sulcus non–small-cell lung carcinomas: long-term results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160) publication-title: J Clin Oncol doi: 10.1200/JCO.2006.08.2826 – volume: 36 start-page: 8541 issue: suppl 15 year: 2018 ident: 10.1016/j.jtho.2018.09.017_bib35 article-title: Neoadjuvant atezolizumab in resectable non-small cell lung cancer (NSCLC): Initial results from a multicenter study (LCMC3) publication-title: J Clin Oncol doi: 10.1200/JCO.2018.36.15_suppl.8541 – volume: 378 start-page: 2078 year: 2018 ident: 10.1016/j.jtho.2018.09.017_bib33 article-title: Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa1801005 – volume: 11 start-page: 1757 year: 1993 ident: 10.1016/j.jtho.2018.09.017_bib77 article-title: Pathologic complete response in advanced non–small-cell lung cancer following preoperative chemotherapy: implications for the design of future non-small-cell lung cancer combined modality trials publication-title: J Clin Oncol doi: 10.1200/JCO.1993.11.9.1757 – volume: 20 start-page: 5359 year: 2014 ident: 10.1016/j.jtho.2018.09.017_bib75 article-title: First FDA approval of neoadjuvant therapy for breast cancer: pertuzumab for the treatment of patients with HER2-positive breast cancer publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-14-1268 – volume: 28 start-page: 3138 year: 2010 ident: 10.1016/j.jtho.2018.09.017_bib17 article-title: Preoperative chemotherapy plus surgery versus surgery plus adjuvant chemotherapy versus surgery alone in early-stage non–small-cell lung cancer publication-title: J Clin Oncol doi: 10.1200/JCO.2009.27.6204 – volume: 25 start-page: 313 year: 2018 ident: 10.1016/j.jtho.2018.09.017_bib11 article-title: Convolutional neural network for histopathological analysis of osteosarcoma publication-title: J Comput Biol doi: 10.1089/cmb.2017.0153 – volume: 102 start-page: 757 year: 2017 ident: 10.1016/j.jtho.2018.09.017_bib38 article-title: Current landscape of targeted therapy in lung cancer publication-title: Clin Pharmacol Ther doi: 10.1002/cpt.810 – volume: 28 start-page: 1843 year: 2010 ident: 10.1016/j.jtho.2018.09.017_bib16 article-title: Surgery with or without preoperative paclitaxel and carboplatin in early-stage non–small-cell lung cancer: Southwest Oncology Group Trial S9900, an intergroup, randomized, phase III trial publication-title: J Clin Oncol doi: 10.1200/JCO.2009.26.1685 – volume: 33 start-page: 4194 year: 2015 ident: 10.1016/j.jtho.2018.09.017_bib54 article-title: Phase III study of surgery versus definitive concurrent chemoradiotherapy boost in patients with resectable stage IIIA(N2) and selected IIIB non–small-cell lung cancer after induction chemotherapy and concurrent chemoradiotherapy (ESPATUE) publication-title: J Clin Oncol doi: 10.1200/JCO.2015.62.6812 – volume: 20 start-page: 776 year: 2002 ident: 10.1016/j.jtho.2018.09.017_bib9 article-title: Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols publication-title: J Clin Oncol doi: 10.1200/JCO.2002.20.3.776 – ident: 10.1016/j.jtho.2018.09.017_bib72 – volume: 386 start-page: 1049 year: 2015 ident: 10.1016/j.jtho.2018.09.017_bib31 article-title: Induction chemoradiation in stage IIIA/N2 non–small-cell lung cancer: a phase 3 randomised trial publication-title: Lancet doi: 10.1016/S0140-6736(15)60294-X – volume: 45 start-page: 228 year: 2009 ident: 10.1016/j.jtho.2018.09.017_bib45 article-title: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) publication-title: Eur J Cancer doi: 10.1016/j.ejca.2008.10.026 – volume: 8 start-page: 1084 year: 2013 ident: 10.1016/j.jtho.2018.09.017_bib57 article-title: Phase II trial of neoadjuvant bevacizumab plus chemotherapy and adjuvant bevacizumab in patients with resectable nonsquamous non-small-cell lung cancers publication-title: J Thorac Oncol doi: 10.1097/JTO.0b013e31829923ec – volume: 13 start-page: 25 year: 2012 ident: 10.1016/j.jtho.2018.09.017_bib20 article-title: Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial publication-title: Lancet Oncol doi: 10.1016/S1470-2045(11)70336-9 – volume: 15 start-page: e42 year: 2014 ident: 10.1016/j.jtho.2018.09.017_bib60 article-title: Pathological response after neoadjuvant chemotherapy in resectable non–small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint publication-title: Lancet Oncol doi: 10.1016/S1470-2045(13)70334-6 – volume: 47 start-page: 669 year: 1989 ident: 10.1016/j.jtho.2018.09.017_bib13 article-title: Preoperative chemotherapy and irradiation for stage III non–small cell lung cancer publication-title: Ann Thorac Surg doi: 10.1016/0003-4975(89)90115-X – volume: 63 start-page: 284 year: 2009 ident: 10.1016/j.jtho.2018.09.017_bib68 article-title: Clinical significance of detecting survivin-expressing circulating cancer cells in patients with non–small cell lung cancer publication-title: Lung Cancer doi: 10.1016/j.lungcan.2008.05.024 – volume: 14 start-page: 488 year: 2013 ident: 10.1016/j.jtho.2018.09.017_bib80 article-title: Preoperative chemotherapy is effective for stage III resectable non–small-cell lung cancer: metaanalysis of 16 trials publication-title: Clin Lung Cancer doi: 10.1016/j.cllc.2013.03.006 – volume: 7 start-page: 825 year: 2012 ident: 10.1016/j.jtho.2018.09.017_bib59 article-title: Histopathologic response criteria predict survival of patients with resected lung cancer after neoadjuvant chemotherapy publication-title: J Thorac Oncol doi: 10.1097/JTO.0b013e318247504a – volume: 24 start-page: 3486 year: 2018 ident: 10.1016/j.jtho.2018.09.017_bib4 article-title: U.S. Food and Drug Administration approval: neratinib for the extended adjuvant treatment of early-stage HER2-positive breast cancer publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-17-3628 – volume: 151 start-page: 221 year: 2009 ident: 10.1016/j.jtho.2018.09.017_bib49 article-title: Positron emission tomography in staging early lung cancer: a randomized trial publication-title: Ann Intern Med doi: 10.7326/0003-4819-151-4-200908180-00132 – volume: 129 start-page: 1651 year: 2011 ident: 10.1016/j.jtho.2018.09.017_bib67 article-title: Detection of circulating tumor cells as a prognostic factor in patients undergoing radical surgery for non–small-cell lung carcinoma: comparison of the efficacy of the CellSearch Assay and the isolation by size of epithelial tumor cell method publication-title: Int J Cancer doi: 10.1002/ijc.25819 – volume: 24 start-page: 1038 year: 2018 ident: 10.1016/j.jtho.2018.09.017_bib44 article-title: The impact of smoking and TP53 mutations in lung adenocarcinoma patients with targetable mutations — the Lung Cancer Mutation Consortium (LCMC2) publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-17-2289 – volume: 86 start-page: 673 year: 1994 ident: 10.1016/j.jtho.2018.09.017_bib15 article-title: A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non–small-cell lung cancer publication-title: J Natl Cancer Inst doi: 10.1093/jnci/86.9.673 – volume: 330 start-page: 153 year: 1994 ident: 10.1016/j.jtho.2018.09.017_bib14 article-title: A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer publication-title: N Engl J Med doi: 10.1056/NEJM199401203300301 – volume: 254 start-page: 438 year: 2011 ident: 10.1016/j.jtho.2018.09.017_bib81 article-title: Cancer trials versus the real world in the United States publication-title: Ann Surg doi: 10.1097/SLA.0b013e31822a7047 – volume: 378 start-page: 1976 year: 2018 ident: 10.1016/j.jtho.2018.09.017_bib34 article-title: Neoadjuvant PD-1 blockade in resectable lung cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa1716078 – volume: 10 start-page: 1515 year: 2015 ident: 10.1016/j.jtho.2018.09.017_bib1 article-title: The IASLC Lung Cancer Staging Project: proposals for the revision of the M descriptors in the forthcoming eighth edition of the TNM classification of lung cancer publication-title: J Thorac Oncol doi: 10.1097/JTO.0000000000000673 – year: 2018 ident: 10.1016/j.jtho.2018.09.017_bib5 article-title: Selection of optimal adjuvant chemotherapy and targeted therapy for early breast cancer: ASCO clinical practice guideline focused update publication-title: J Clin Oncol doi: 10.1200/JCO.2018.78.8604 – volume: 29 start-page: 1853 year: 2018 ident: 10.1016/j.jtho.2018.09.017_bib61 article-title: Pathologic features of response to neoadjuvant anti–PD-1 in resected non–small cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC) publication-title: Ann Oncol doi: 10.1093/annonc/mdy218 – volume: 55 start-page: 1226 year: 1985 ident: 10.1016/j.jtho.2018.09.017_bib12 article-title: Combined surgery, intraoperative brachytherapy, and postoperative external radiation in stage III non–small cell lung cancer publication-title: Cancer doi: 10.1002/1097-0142(19850315)55:6<1226::AID-CNCR2820550614>3.0.CO;2-6 – volume: 26 start-page: 778 year: 2008 ident: 10.1016/j.jtho.2018.09.017_bib6 article-title: Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27 publication-title: J Clin Oncol doi: 10.1200/JCO.2007.15.0235 – volume: 6 start-page: 1382 year: 2016 ident: 10.1016/j.jtho.2018.09.017_bib36 article-title: Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease publication-title: Cancer Discov doi: 10.1158/2159-8290.CD-16-0577 – volume: 11 start-page: 537 year: 2016 ident: 10.1016/j.jtho.2018.09.017_bib19 article-title: Adaptive neoadjuvant chemotherapy guided by (18)F-FDG PET in resectable non–small cell lung cancers: the NEOSCAN trial publication-title: J Thorac Oncol doi: 10.1016/j.jtho.2015.12.104 – volume: 34 start-page: 2526 year: 2016 ident: 10.1016/j.jtho.2018.09.017_bib55 publication-title: J Clin Oncol doi: 10.1200/JCO.2015.65.5167 – volume: 545 start-page: 446 year: 2017 ident: 10.1016/j.jtho.2018.09.017_bib69 article-title: Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution publication-title: Nature doi: 10.1038/nature22364 – volume: 100 start-page: 121 year: 2008 ident: 10.1016/j.jtho.2018.09.017_bib7 article-title: Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial publication-title: J Natl Cancer Inst doi: 10.1093/jnci/djm287 – volume: 7 start-page: 841 year: 2012 ident: 10.1016/j.jtho.2018.09.017_bib78 article-title: Pathologic complete response to preoperative chemotherapy predicts cure in early-stage non-small-cell lung cancer: combined analysis of two IFCT randomized trials publication-title: J Thorac Oncol doi: 10.1097/JTO.0b013e31824c7d92 – volume: 20 start-page: 1989 year: 2002 ident: 10.1016/j.jtho.2018.09.017_bib30 article-title: Long-term results of combined-modality therapy in resectable non–small-cell lung cancer publication-title: J Clin Oncol doi: 10.1200/JCO.2002.08.092 – volume: 10 start-page: 1675 year: 2015 ident: 10.1016/j.jtho.2018.09.017_bib2 article-title: The International Association for the Study of Lung Cancer Lung Cancer Staging Project: proposals for the revision of the N descriptors in the forthcoming 8th edition of the TNM classification for lung cancer publication-title: J Thorac Oncol doi: 10.1097/JTO.0000000000000678 – volume: 78 start-page: 1903 year: 2004 ident: 10.1016/j.jtho.2018.09.017_bib52 article-title: Repeat FDG-PET after neoadjuvant therapy is a predictor of pathologic response in patients with non–small cell lung cancer publication-title: Ann Thorac Surg doi: 10.1016/j.athoracsur.2004.06.102 – volume: 120 start-page: 1584 year: 2001 ident: 10.1016/j.jtho.2018.09.017_bib58 article-title: Grading of tumor regression in non–small cell lung cancer: morphology and prognosis publication-title: Chest doi: 10.1378/chest.120.5.1584 – volume: 384 start-page: 164 year: 2014 ident: 10.1016/j.jtho.2018.09.017_bib8 article-title: Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis publication-title: Lancet doi: 10.1016/S0140-6736(13)62422-8 – volume: 13 start-page: 323 year: 2018 ident: 10.1016/j.jtho.2018.09.017_bib62 publication-title: J Thorac Oncol doi: 10.1016/j.jtho.2017.12.001 – volume: 311 start-page: 1998 year: 2014 ident: 10.1016/j.jtho.2018.09.017_bib43 article-title: Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs publication-title: JAMA doi: 10.1001/jama.2014.3741 – volume: 19 start-page: 4911 year: 2013 ident: 10.1016/j.jtho.2018.09.017_bib76 article-title: First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-13-1212 – volume: 375 start-page: 1823 year: 2016 ident: 10.1016/j.jtho.2018.09.017_bib32 article-title: Pembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa1606774 |
| SSID | ssj0045048 |
| Score | 2.5889397 |
| SecondaryResourceType | review_article |
| Snippet | This Review Article provides a multi-stakeholder view on the current status of neoadjuvant therapy in lung cancer. Given the success of oncogene-targeted... ABSTRACTThis Review Article provides a multi-stakeholder view on the current status of neoadjuvant therapy in lung cancer. Given the success of... |
| SourceID | swepub proquest pubmed crossref wolterskluwer elsevier |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 1818 |
| SubjectTerms | Induction chemotherapy Neoadjuvant therapy Pathologic response Preoperative therapy Resectable lung cancer |
| Title | Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer |
| URI | https://dx.doi.org/10.1016/j.jtho.2018.09.017 https://ovidsp.ovid.com/ovidweb.cgi?T=JS&NEWS=n&CSC=Y&PAGE=fulltext&D=ovft&AN=01243894-201812000-00005 https://www.ncbi.nlm.nih.gov/pubmed/30268698 https://www.proquest.com/docview/2115274261 http://kipublications.ki.se/Default.aspx?queryparsed=id:139661769 |
| Volume | 13 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1ba9swFBZZCmNjjN2X3dBg7CW4yJbs2I9ZaClt04etZX0TsiWTpJsz2pjBfsJ-9c6xZNXJ2rL1xRjJF1nn89En6VwI-RAl3MQ5VwEM3ywQOSsDlSZZoEpdCl7yNG5M_qdHyd6J2D-NT3u93x2rpXqVbxe_rvQruY1UoQzkil6y_yFZ_1AogHOQLxxBwnD8Jxm3wZWQMdY22PJuEyOkMWx3PpTNfsCRWSq9qIE2r9DIAgMJ4ErHYY27_ij482tY6moGGCnmBTykWFuB_4RarVrNlM3QNdcGXjPd9tWOGKPl4XDsiyczZdX-vvo-N8MdXzEtJuja5W1QkPy6WrcmEaYb9h3eWWbNlhOYSxLADMquH5jLspDbZE5eIfMu8KKOegU6knaGalBH4ZXDgF2RWECvzdDBM0ybWLbWSXQjvPYXbAK2Ch7GcVHuDtmKYMrB-mRrfPD560E7rouYNbnY_Gc4FyxrLbj5putozt_TGB-j9j558HOJJhIXZ42HRIfnHD8iD53o6dii7THpmeoJuTt1JhhPyaEDHbWgowA6akFHu6Cjy4p2QEcd6Oi8ogg6akH3jJzs7hxP9gKXkiMoYphKB0YXeZhniRIRzMzTHP5GrTUX2SgOc6A5RmulYSxHNV-WUW44TwRD0j6KIxYr_pz0q2VlXhLKMFGCHinGCi1SbjJMFMCLDBh5mprEDEjY9qAsXLx6TJvyTbaGiQuJvS6x1yXLJPT6gAz9PT9stJYbr45bwUjHNy2PlICjG-9730pRgjLGHTZVmWV9IaMQs0TjqsSAvLDi9e3gLEpAC6YD8tHK29dghHdXdAZnRoo0jgRcGKzhQVrPaGhBJGCaIYKoCbbnQkOw-NUtP-c1uXf5D78h_dV5bd4C017l79wv8AdjPc-U |
| linkProvider | Library Specific Holdings |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Current+Status+and+Future+Perspectives+on+Neoadjuvant+Therapy+in+Lung+Cancer&rft.jtitle=Journal+of+thoracic+oncology&rft.au=Blumenthal%2C+Gideon+M.&rft.au=Bunn%2C+Paul+A.&rft.au=Chaft%2C+Jamie+E.&rft.au=McCoach%2C+Caroline+E.&rft.date=2018-12-01&rft.pub=Elsevier+Inc&rft.issn=1556-0864&rft.eissn=1556-1380&rft.volume=13&rft.issue=12&rft.spage=1818&rft.epage=1831&rft_id=info:doi/10.1016%2Fj.jtho.2018.09.017&rft.externalDocID=S1556086418331290 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1556-0864&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1556-0864&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1556-0864&client=summon |